The role of exercise in treating depression has been studied extensively in recent years. For example, Rethorst *et al* ([@r8]) carried out a meta-analysis of 58 randomised controlled trials, and found that groups whose treatment incorporated exercise had significantly lower depression scores than controls. De Zeeuw *et al* ([@r4]) showed that exercise could have preventive potential, as it was found to reduce the likelihood of depression in high-risk employees with sedentary jobs and an inactive lifestyle. Exercise has also been reported to reduce relapse rates. For example, Babyak *et al* ([@r2]) found that participants with major depressive disorder who used exercise therapy alone had significantly lower relapse rates than those who received medication.

Despite these promising findings and its low cost, the effectiveness of exercise is yet to be fully addressed in the psychosocial treatment literature or incorporated into mainstream treatment practice. For example, the National Institute for Health and Clinical Excellence (NICE, [@r6]) recommended 'structured group physical activity' only as a low-intensity psychosocial intervention for subthreshold depressive symptoms, or depression with chronic physical health problems. This may be because many studies have been criticised for their methodological limitations and incomplete literature searches (Rethorst *et al*, [@r8]); indeed, the classification and duration of exercise are not specified in the majority of reports. Of further note is that the efficacy of exercise in a maintenance capacity remains largely unexplored. Thus, our rationale was to investigate the role of exercise alongside antidepressant medication as a post-remission maintenance therapy, in terms of reducing both the severity of psychopathology and relapse rates.

Method {#s1}
======

The 50 patients recruited were attending the psychiatric out-patient department of Sir Sunderland Hospital, Banaras Hindu University, India. Selection was made (via referrals from two senior psychiatrists at the hospital) by the researcher who carried out the post-treatment evaluations. The following selection criteria were used: age 15--45 years, in order to cope with the physical exercise regimea diagnosis of major depressive or dysthymic disorder, according to DSM-IV-TR criteria (American Psychiatric Association, [@r1])absence of any comorbid psychiatric illnessno major cardiac or orthopaedic illness that would contraindicate exercise.

Ethical approval was granted by the University's research ethics committee.

After inclusion in the study, patients were prescribed sertraline (200 mg/day -- the maximum permitted daily dose) and alprazolam (1 mg/day) for 3--4 weeks in order to achieve remission of clinical depression. Once significant remission -- defined as scoring less than 16 on the 21-item Hamilton Rating Scale for Depression (HRSD; Hamilton, [@r5]) -- was obtained, patients were randomly allocated to groups; blinding was not possible, however, as participants were necessarily aware of the treatment group they were in and the researcher who administered exercise therapy also did the follow-up assessment of psychopathology.

Pre-treatment evaluation {#s1a}
------------------------

The researcher assessed the following using a semi-structured pro forma: sociodemographic and clinical dataseverity of depressive psychopathology (using the HRSD, plus a structured interview guide)stressful life events (lifetime and past 3 months), using the 51-item Presumptive Stressful Life Events Scale (PSLES; Singh *et al*, [@r9]) (a culturally appropriate instrument)melancholic and atypical features of depression (as per DSM-IV-TR)baseline heart rate (mean taken from three 1-minute time slots)fitness levels using the Harvard Step Test, to monitor compliance with the exercise programme (Brouha, [@r3]).

Treatment {#s1b}
---------

Both groups continued to receive sertraline (200 mg/day) and alprazolam (1 mg/day) and did not take part in any form of counselling or psychotherapy. For the medication-plus-exercise group, participants also received training in daily exercise therapy. That therapy consisted of a 5-minute warm-up, 15 minutes of stationary running, and a 10-minute cool-down, this being convenient and economical for all participants regardless of gender or location and within guidelines on exer cise (Whaley *et al*, [@r10]). Participants were also advised not to perform any other exercise beyond usual daily activities. Heart rate recordings were made in order to adjust the intensity of exercise to keep within the target heart rate zone, this being 60--84% of the maximum achievable heart rate (Whaley *et al*, [@r10]); exercise sessions at home were logged and monitored by carers, and the logs were reviewed by the researcher at every follow-up. None of the participants or their carers reported missing any exercise sessions or cutting sessions short. Follow-up was at 6-weekly intervals for 24 weeks for all participants, and HRSD and PSLES scores were assessed on each occasion. The medication-plus-exercise group also received refresher exercise training and the Harvard Step Test was performed at every follow-up.

Analysis {#s1c}
--------

Statistical tests used were the chi-square and Student *t*-test. Epi Info 6 software, version 6.04a, was used to analyse the data.

Results {#s2}
=======

Although all 50 patients initially agreed to participate, seven did not complete the study (three from the medication-plus-exercise group and four from the medication-only group). [Table 1](#t1){ref-type="table"} shows the sample characteristics and features of depression, which were evenly distributed between the groups. [Table 2](#t2){ref-type="table"} shows the inter-group comparisons at all 6-weekly follow-ups. The medication-plus-exercise group showed a greater improvement in HRSD scores (change in score from baseline) than the medication-only group from the first follow-up, at 6 weeks, and this difference became statistically significant at weeks 12 (*P* = 0.04, *t* = 2.10) and 24 (*P* = 0.02, *t* = 2.42); there was no significant difference between the groups' PSLES scores at any follow-up point.

###### Baseline characteristics of the sample

  -----------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable                                                                      Medication-only group (*n* = 25)   Medication-and-exercise group (*n* = 25)
  ----------------------------------------------------------------------------- ---------------------------------- ------------------------------------------
  Number (%) female                                                             9 (60)                             6 (40)

  Number (%) male                                                               16 (46)                            19 (54)

  Usual degree of physical activity: number (%)\                                \                                  \
   sedentary\                                                                   15 (65)\                           8 (35)\
   light\                                                                       9 (41)\                            13 (59)\
   moderate                                                                     1 (20)                             4 (80)

  Mean (s.d.) age (years)                                                       29.6 (8.2)                         30.5 (8.9)

  Mean (s.d.) PSLES score for lifetime                                          216.2 (124.9)                      188.0 (86.3)

  Mean (s.d.) PSLES score for last 3 months                                     105.0 (72.6)                       107.2 (65.3)

  Mean (s.d.) HRSD score[\*](#t1fn1){ref-type="table-fn"}                       23.2 (4.2)                         22.8 (3.7)

  Mean (s.d.) number of melancholic features[\*](#t1fn1){ref-type="table-fn"}   1.2 (1.6)                          0.7 (1.1)

  Mean (s.d.) number of atypical features[\*](#t1fn1){ref-type="table-fn"}      0.1 (0.33)                         0.0 (0.3)
  -----------------------------------------------------------------------------------------------------------------------------------------------------------

HRSD, Hamilton Rating Scale for Depression; PSLES, Presumptive Stressful Life Events Scale.

Between group comparisons were non-significant.

###### Mean (s.d.) improvement (difference from baseline) in score on the Hamilton Rating Scale for Depression

  Follow-up   Medication-only group   Medication-and-exercise group   *t*    d.f.   *P*
  ----------- ----------------------- ------------------------------- ------ ------ --------
  6 weeks     2.6 (5.3)               4.1 (3.4)                       1.17   46     \>0.05
  12 weeks    2.3 (5.2)               5.0 (3.4)                       2.10   45     0.04
  18 weeks    3.0 (6.5)               5.6 (5.1)                       1.45   42     \>0.05
  24 weeks    1.0 (7.0)               5.6 (5.4)                       2.42   41     0.02

Relapse rates were also recorded via subjective reports and as a measured increase of \>50% from baseline HRSD scores (Neumeister *et al*, [@r7]). In total, nine patients relapsed, two from the medication-plus-exercise group (both in week 18) and seven from the medication-only group (one relapse in week 6, two in week 12 and four in week 24). This difference in relapse rates did not reach significance (Fisher's exact test: one-tailed, *P* = 0.07; two-tailed, *P* = 0.14).

Discussion {#s3}
==========

We found that the maintenance treatment of medication-plus-exercise resulted in significantly lower HRSD scores than medication alone at 12-week and 24-week assessments, as well as a promising reduction of relapse rates. These differences were not considered to be due to extraneous life events, as there was no significant difference between the two groups' PSLES scores. These findings are in line with Rethorst *et al*'s ([@r8]) meta-analysis in terms of the potential for exercise to lower depression scores, and with the finding from Babyak *et al* ([@r2]) that exercise is effective in reducing relapse. We found no studies, however, on the combined role of exercise and antidepressant medication as a maintenance therapy for depressive disorder. The present findings suggest a potential role for exercise as a protective agent during remission, and one which might reduce long-term cost.

The study was limited in several ways. There is potential for bias via use of a clinician-rated tool such as the HRSD, particularly in an unblinded study. However, to reduce this, the same experienced assessor was used for the pre-intervention and follow-up assessments and a second assessor made random cross-checks at least once for every participant. Assessors completed the rating scales with the participants through discussion. The sample size was limited to 50, which precluded analysis of potential confounds. For example, the medication-only group was randomly allocated a greater proportion of sedentary members from the outset. There was also an unequal proportion of male/female participants; however, this reflected the population of patients within the hospital.

A further limitation was the lack of comparison with an exercise-only group. It is possible that the exercise group may have derived social gain from the increased contact with carers and researchers; interestingly, Babyak *et al* ([@r2]) raise the point that psychological factors such as proactive agency may be engaged via choosing to exercise.

A further issue for the current study was the drop in the rate of improvement for the medication-only group at week 24. The reasons for this are unclear; however, such a change dictates that studies with longer periods of assessment are needed to make stronger interpretations. Thus, future studies could benefit from: larger and more representative samples; extended follow-up periods; additional outcome measures (including patient-rated scales); and the inclusion of further control groups, such as exercise only, social contact only, and group versus solitary exercise.

In conclusion, this study adds to the growing evi dence base that suggests exercise is valuable in the treatment of depressive disorders. In particular, we highlight its potential role as a supplementary maintenance treatment during remission. It is worth highlighting that, despite the relatively short time for which the participants exercised, there were measurable benefits. We believe this area of research warrants further attention, particularly as exercise provides a low-cost, flexible and easily implemented treatment with minimal adverse effects, and especially where costly delays in receiving mainstream psychological interventions are commonplace.
